Literature DB >> 32767512

Revisiting nonclassical HLA II functions in antigen presentation: Peptide editing and its modulation.

Miguel Álvaro-Benito1, Christian Freund1.   

Abstract

The nonclassical major histocompatibility complex of class II molecules (ncMHCII) HLA-DM (DM) and HLA-DO (DO) feature essential functions for the selection of the peptides that are displayed by classical MHCII proteins (MHCII) for CD4+ Th cell surveillance. Thus, although the binding groove of classical MHCII dictates the main features of the peptides displayed, ncMHCII function defines the preferential loading of peptides from specific cellular compartments and the extent to which they are presented. DM acts as a chaperone for classical MHCII molecules facilitating peptide exchange and thereby favoring the binding of peptide-MHCII complexes of high kinetic stability mostly in late endosomal compartments. DO on the other hand binds to DM blocking its peptide-editing function in B cells and thymic epithelial cells, limiting DM activity in these cellular subsets. DM and DO distinct expression patterns therefore define specific antigen presentation profiles that select unique peptide pools for each set of antigen presenting cell. We have come a long way understanding the mechanistic underpinnings of such distinct editing profiles and start to grasp the implications for ncMHCII biological function. DM acts as filter for the selection of immunodominant, pathogen-derived epitopes while DO blocks DM activity under certain physiological conditions to promote tolerance to self. Interestingly, recent findings have shown that the unexplored and neglected ncMHCII genetic diversity modulates retroviral infection in mouse, and affects human ncMHCII function. This review aims at highlighting the importance of ncMHCII function for CD4+ Th cell responses while integrating and evaluating what could be the impact of distinct editing profiles because of natural genetic variations.
© 2020 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD4+ T cell epitope; HLA-DM; HLA-DO; MHC class II; nonclassical MHCII; peptide editing; peptidome

Mesh:

Substances:

Year:  2020        PMID: 32767512     DOI: 10.1111/tan.14007

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  6 in total

1.  Natural variation of ncHLAII molecules: challenges and perspectives.

Authors:  Miguel Álvaro-Benito
Journal:  Cell Mol Immunol       Date:  2022-08-26       Impact factor: 22.096

Review 2.  Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2021-06-17       Impact factor: 7.268

Review 3.  Fate of MHCII in salmonids following 4WGD.

Authors:  Unni Grimholt; Morten Lukacs
Journal:  Immunogenetics       Date:  2020-11-23       Impact factor: 2.846

4.  Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment.

Authors:  Juha P Väyrynen; Koichiro Haruki; Sara A Väyrynen; Mai Chan Lau; Andressa Dias Costa; Jennifer Borowsky; Melissa Zhao; Tomotaka Ugai; Junko Kishikawa; Naohiko Akimoto; Rong Zhong; Shanshan Shi; Tzuu-Wang Chang; Kenji Fujiyoshi; Kota Arima; Tyler S Twombly; Annacarolina Da Silva; Mingyang Song; Kana Wu; Xuehong Zhang; Andrew T Chan; Reiko Nishihara; Charles S Fuchs; Jeffrey A Meyerhardt; Marios Giannakis; Shuji Ogino; Jonathan A Nowak
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

5.  Hidden Markov Modeling with HMMTeacher.

Authors:  Camilo Fuentes-Beals; Alejandro Valdés-Jiménez; Gonzalo Riadi
Journal:  PLoS Comput Biol       Date:  2022-02-10       Impact factor: 4.475

Review 6.  HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation.

Authors:  Tiira Johansson; Jukka Partanen; Päivi Saavalainen
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.